• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[关于肺结核细菌分离程度及结核分枝杆菌耐药性的外科治疗长期结果]

[Long-term results of surgical treatment of pulmonary tuberculosis wtih respect to the extent of bacterial isolation and to drug resistance of Mycobacterium tuberculosis].

作者信息

El'kin A V, Repin Iu M, Levashev Iu N

出版信息

Probl Tuberk Bolezn Legk. 2003(5):28-31.

PMID:12899013
Abstract

The remote postoperative results were followed up for as long as up to 10 years. It was established in case of abacillary patients that the frequency rate of relapses was minimal ranging from 3.6% in the group of patients operated for tuberculosis and caseous-necrotic tuberculosis to 11.5% in fibrous-cavernous tuberculosis. Patients with bacterial discharge, primarily of the extensive nature, had more often relapses (19.4% in operated patients for caseous-necrotic tuberculosis and 31.7% in patients operate for fibrous-cavernous tuberculosis). Drug resistance (DR) of Mycobacterium tuberculosis (MBT) to three and more anti-TB preparations essentially increase a possibility of relapses in all clinical forms of tuberculosis with maximum threat being in patients with fibrous-cavernous lesions (36%). As for the repeatedly operated patients for postoperative relapses involving DR MBT to isoniazid and rifampicin, only slightly above 50% of them survived 5 years after surgery; the index of the 5-year survival was 33% among the patients with DR to 4 and more drugs.

摘要

对术后远期结果进行了长达10年的随访。结果发现,在非菌阳患者中,复发率极低,从接受结核和干酪坏死性结核手术的患者组中的3.6%到纤维空洞性结核患者组中的11.5%不等。有排菌情况的患者,主要是广泛性排菌的患者,复发更为频繁(接受干酪坏死性结核手术的患者中复发率为19.4%,接受纤维空洞性结核手术的患者中复发率为31.7%)。结核分枝杆菌(MTB)对三种及以上抗结核制剂的耐药性(DR)基本上增加了所有临床类型结核病复发的可能性,其中纤维空洞性病变患者面临的威胁最大(36%)。对于因术后复发而再次接受手术、且MTB对异烟肼和利福平耐药的患者,术后5年仅有略高于50%的患者存活;对4种及以上药物耐药的患者,5年生存率为33%。

相似文献

1
[Long-term results of surgical treatment of pulmonary tuberculosis wtih respect to the extent of bacterial isolation and to drug resistance of Mycobacterium tuberculosis].[关于肺结核细菌分离程度及结核分枝杆菌耐药性的外科治疗长期结果]
Probl Tuberk Bolezn Legk. 2003(5):28-31.
2
[Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].[耐异烟肼或耐利福平结核病的特征及治疗结果]
Kekkaku. 2003 Oct;78(10):611-7.
3
Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.肺切除术联合基于异烟肼和利福平的药物治疗用于耐多药和广泛耐药结核病患者。
Int J Infect Dis. 2009 Mar;13(2):170-5. doi: 10.1016/j.ijid.2008.06.001. Epub 2008 Sep 2.
4
[Efficacy of treatment for pulmonary tuberculosis with multidrug mycobacterial resistance].[多药耐药性肺结核的治疗效果]
Probl Tuberk. 2002(12):18-23.
5
[Ways of overcoming drug resistance in patients with pulmonary tuberculosis].[肺结核患者克服耐药性的方法]
Probl Tuberk. 2002(3):16-8.
6
[Drug resistant tuberculosis in children and adolescents].[儿童和青少年耐多药结核病]
Probl Tuberk. 2003(1):25-8.
7
[Primary drug resistance of Mycobacterium tuberculosis in patients with new-onset destructive pulmonary tuberculosis].新发破坏性肺结核患者中结核分枝杆菌的原发性耐药性
Probl Tuberk Bolezn Legk. 2009(4):37-9.
8
[Development of antituberculous drugs: current status and future prospects].[抗结核药物的研发:现状与未来前景]
Kekkaku. 2006 Dec;81(12):753-74.
9
[Long-term results of treatment for drug-resistant pulmonary tuberculosis in socially adapted patients].[社会适应良好患者耐药性肺结核治疗的长期结果]
Probl Tuberk Bolezn Legk. 2004(3):26-8.
10
[Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].[含氟喹诺酮类抗结核药物的短期治疗方案用于耐利福平肺结核的疗效与安全性研究]
Zhonghua Liu Xing Bing Xue Za Zhi. 2009 Feb;30(2):179-83.